On Tuesday, Shares of SouFun Holdings Ltd. (NYSE:SFUN), gained 1.45% to $9.08, as Technology stocks were hanging on to slim gains late in Tuesday’s session after earlier reversing small losses, with shares of technology companies in the S&P 500 advancing about 0.2%.
SouFun Holdings, declared that it will hold its 2015 annual general meeting of shareholders at Building 5, Zone 4, Hanwei International Plaza, No. 186 South 4th Ring Road, Fengtai District, Beijing 100160, the People’s Republic of China on July 3, 2015 at 10:30 a.m. (local time).
SouFun Holdings Limited operates a real estate Internet portal, and home furnishing and improvement Websites in the People’s Republic of China. The company offers marketing services on its Websites, primarily through advertisements to real estate developers in the marketing phase of new property developments, in addition to real estate agencies; and suppliers of home furnishing and improvement, and other home-related products and services.
Shares of Fiat Chrysler Automobiles N.V. (NYSE:FCAU), inclined 1.41% to $15.79, during its last trading session.
Fiat Chrysler Automobiles, celebrates 90 years of building quality, beautiful vehicles that are loaded with style, innovative technology and the comfort customers desire, at an affordable price
2016 model year Chrysler 200, 300 and Town & Country to offer 90th Anniversary Packages with more content at a great value
Anniversary packages will be offered on the volume models, adding value for the customer who will most appreciate it.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 0.40% gain, and closed at $67.33.
Portola Pharmaceuticals (PTLA), Bristol-Myers Squibb Company, and Pfizer Inc. (PFE) declared full results from the second part of the Phase 3 ANNEXA(TM)-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors — Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years.
This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa stated. Mild infusion reactions were stated in six subjects: four in the andexanet arm and two in the placebo arm. No subjects suspended the study due to an adverse event. The full data set was presented recently in a Late-Breaking Clinical Trial oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
